Genelabs Technologies

Peter R. Young, Ph.D. has joined Genelabs Technologies as vice president, biology. Dr. Young joins the company from Celera Genomics, where he served as vice president, biology. He reports to Ronald C. Griffith, Ph.D., Genelabs’ chief scientific officer.

Prior to Celera, Dr. Young was vice president, research at Sugen, Inc. and previously was director, metabolic disease with DuPont Pharmaceuticals and Bristol Myers Squibb and director, molecular biology with SmithKline Beecham. He is an inventor on 44 U.S. patents and has published more than 100 abstracts and papers.

Also, the company’s chief financial officer, Matthew Loar, will be leaving the company on September 1st to accept a position at a biotechnology company. Genelabs has initiated a search for a replacement, and Mr. Smith will assume Mr. Loar’s responsibilities until a new chief financial officer is named.